慢性肾脏病高磷血症治疗新靶点

Progress of therapeutic targets for hyperphosphatemia in chronic kidney disease

高磷血症是慢性肾脏病(CKD)的常见并发症之一,是引起继发性甲状旁腺功能亢进、肾性骨营养不良、血管及组织钙化的重要原因。目前对于CKD高磷血症患者的管理,仅局限于限磷饮食、口服磷酸盐结合剂和充分透析。因此,对CKD高磷血症患者治疗新靶点的研究至关重要。目前已有新的限制磷酸盐摄入的治疗方法,直接以细胞外肠内磷酸盐转运途径为靶目标,减少肠道对磷酸盐的吸收。本文通过介绍CKD高磷血症患者肠道调节磷酸盐吸收的机制,并在此基础上,讨论CKD高磷血症患者治疗的新靶点。

Hyperphosphatemia is one of the common complications of chronic kidney disease and an important cause of secondary hyperparathyroidism,renal osteodystrophy,vascular and tissue calcification.The current management of patients with chronic kidney disease with hyperphosphatemia mainly consists of a phosphorus-restricted diet,oral phosphate binders and adequate dialysis.Therefore,it is important to find new therapeutic targets for hyperphosphatemia in chronic kidney disease.Currently,there is a new treatment method for limiting phosphate intake,which directly targets extracellular enteral phosphate transport pathway and reduces the absorption of phosphate in intestine.In this review,mechanisms of intestinal regulation of phosphate absorption in patients with chronic kidney disease are introduced.Based on this,new therapeutic targets for hyperphosphatemia are discussed.